Buprenorphine maintenance treatment in patients with opioid use disorder diagnosed with COVID-19.
J Opioid Manag
; 16(6): 405-407, 2020.
Article
in English
| MEDLINE | ID: covidwho-1022156
ABSTRACT
The current COVID-19 pandemic is impacting individuals with pre-existing opioid use disorder (OUD), many of whom are receiving daily dosed buprenorphine treatment. There is a limited clinical experience with how to manage buprenorphine maintenance in infected individuals. Published guidance considers the possibility of dosage or formulation changes. This case series reports on 10 cases involving individuals with OUD who were receiving daily dosed buprenorphine and contracted COVID-19. It was found that for those with mild-moderate COVID-19 disease, in the absence of significant respiratory symptoms, changes to buprenorphine management including changes to daily dose, were not necessary.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Buprenorphine
/
Opiate Substitution Treatment
/
COVID-19
/
Opioid-Related Disorders
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
J Opioid Manag
Journal subject:
Neurology
/
Psychophysiology
/
Drug Therapy
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS